Hematopoietic function of some aplastic anemia (AA) patients is dependent on the administration of cyclosporine (CyA). To investigate whether certain HLA class II genes are associated with susceptibility to such CyA-dependent AA, we determined the HLA class II alleles of 59 AA patients treated with CyA. Among 26 patients successfully treated with CyA, 13 required a small dose of CyA to maintain stable hematopoiesis. Of these 13 AA patients, 10 shared an HLA class II haplotype of DRB1*1501-DQA1*0102-DQB1*0602. None of the 13 responders who obtained a sustained remission off CyA therapy possessed this haplotype. In the 10 patients who shared the HLA class II haplotype, singlestrand conformation polymorphism analysis of each gene fragment of this haplotype failed to detect a polymorphism MMUNOSUPPRESSIVE therapies such as antithymocyte globulin (ATG), antilymphocyte globulin (ALG), and cyclosporine (CyA) have been used successfully for treatment of acquired aplastic anemia (AA).',' Because more than half of AA patients respond to such therapy and achieve hematologic remission, immune-mediated suppression of hematopoiesis has been considered to be the most important mechanism responsible for bone marrow failure in AA.' However, a response to ATGIALG in patients with AA does not necessarily indicate an immune-mediated mechanism, because ATG/ALG may produce remission through a stimulatory effect on hematopoietic progenitor cells rather than through immunosuppressive acti0ns.4.~ Response to monotherapy with CyA may be more suggestive of immune mechanisms in the pathogenesis of AA than response to ATG because the action of CyA is confined to suppression of lymphokine production by T cells6 However, it is possible that AA patients in remission after CyA therapy may have recovered independently of the drug; spontaneous remission has occurred in some cases.
Some AA patients who were successfully treated with CyA experienced a recurrence of pancytopenia after dose reduction or cessation of CyA and then recovered after dose escalation or reinitiation of the drug.'.' These patients usually require a small dose of CyA to maintain stable hematopoiesis. In patients with AA showing CyA-dependent response of hematopoiesis (CyA-dependent AA), it is reasonable to presume that immune mechanisms play an important role in bone marrow failure.
It has been shown that the development of several autoimmune diseases, such as insulin-dependent diabetes mellitus and multiple sclerosis, is strongly associated with the presentation of certain HLA-DR phenotypes.' Recent analysis of HLA class I1 genes of these patients has shown that gene alleles or gene haplotypes corresponding to certain DR serotypes are more strongly correlated with susceptibility than the serotype itself.'" We and others have previously shown that AA patients who possess HLA-DR2 are likely to respond to immunosuppressive therapy."." The HLA-DR2 antigen has serologically been split into DR15 and DR16. If an immune-mediated subset of AA patients were defined appropriately, we might be able to identify HLA class I1 
MATERIALS AND METHODS

Patients.
A total of 59 Japanese patients with idiopathic AA were studied; they were treated with CyA for more than 3 months at clinics participating in the Intractable Hemopoietic Disease Research Group supported by the Ministry of Health and Welfare of Japan. Table 1 shows the characteristics of these patients. Response criteria were defined as a resolution of all transfusion requirements and a 2 2 g/dL increase in hemoglobin as compared with pretreatment levels. Dependency on CyA was diagnosed when an AA patient successfully treated with CyA alone or as combined therapy developed pancytopenia after dose reduction or cessation of CyA and improved after dose escalation or reinitiation of CyA.
Determination of HL4 class II alleles. High molecular weight DNA was extracted from leukocytes of patients using a standard method. All patients gave informed consent for drawing of blood for genotyping of HLA class 11. Second exons of DRB 1, DQAl, and DQBl genes were amplified using the polymerase chain reaction (PCR) with specific primers, and each allele was typed using the restriction fragment-length polymorphism method as described prev i o~s l y . '~. '~ The frequency of an HLA class I1 haplotype in these patients was compared with that in a control population consisting of 916 unrelated Japanese individual^.'^ This control population was considered valid for comparison with CyA-treated patients in this Abbreviations: HDMP, high-dose methylprednisolone; PSL, prednisolone; AS, anabolic steroid; G-CSF, granulocyte colony-stimulating factor; M:F, makfemale ratio.
NAKAO ET AL study because both populations originated from the same area in Japan.
Screening for sequence polymorphisms in HLA cluss I1 ulleles.
PCR-single-strand conformation polymorphism (SSCP) analysis for the amplified products on each allele was performed as previously described.16 PCR products were mixed with the same volume of loading solution containing formamide (final concentration, SO%), incubated at 96°C for 5 minutes, and rapidly chilled on ice. Samples were electrophoresed at a constant voltage o f 150 V for 4 hours on an 8% polyacrylamide gel. Gels were dried, and D N A was visualized using a silver-staining kit (Daiichi Chemical CO Ltd, Tokyo, Japan).
Sfuristics. Differences Japanese population (5.6%; P < ,001; x' analysis), whereas the frequency of the other two haplotypes in these patients was not statistically different from that of n o d controls (P = .l5 for DRB1*1502-DQA1*0103-DQB1*0601 and P = .48 for DRB1*0405-DQA1*0301-DQB1*0401). 15 The haplotype of DRB1*1501-DQAI*0102-DQB1*0602 was found in none of the 13 patients who had a sustained remission after CyA therapy was discontinued.
Relationship between an HLA class iI haplotype and response to CyA therapy. Among the 59 patients, the haplotype of DRB1*1501-DQA1*0102-DQB1*0602 was found in 14. Another haplotype DRB1*1502-DQA1*0103-DQB1*0601, which is associated with HLA-DR2 as well as the DRB 1 * 1501 -DQA 1 *0102-DQB 1 *0602 haplotype, was detected in 22 patients. The 59 AA patients were divided into patients with DRB1*1501-DQA1*0102-DQB1*0602 (group A), patients with DRB1*1502-DQA1*0103-DQB1*0601 (group B), and those without the two haplotypes (group C), and response to CyA therapy was compared among these three groups. When the three groups were compared for other prognostic factors, there was no significant difference in disease seventy (neutrophil counts; P = .34; KruskalWallis test), disease duration (months; P = .23), and age ( P = .14). The response rate in group A (10 of 14 [71%]) was significantly higher than that in group B (8 of 22 [36%]; P = 043; Fisher's exact test) and in group C (8 of 23 [35%]; P = .033). When the patients whose disease duration before initiation of CyA therapy was more than 5 years were excluded from these patients, the difference was significant as well ( Fig 1A) . A total of 91% (10 of 11) of group A responded to therapy, whereas 40% of group B (P = .007) and 53% of group C ( P = .049) responded.
Relarionship between an HLA class ii haplotype and CyAdependent hematopoiesis in AA. When a proportion of CyA-dependent cases in responders was compared between group A and others, the difference was more evident ( Fig  1B) . All responders in group A (10 of 10 [100%]) became CyA-dependent, whereas only 38% (3 of 8) of those in group B showed dependency to CyA therapy. None of the responders (8) in group C in this study were CyA-dependent.
Analysis of pofymorphic sequences in HLA class II alleles of patients with CyA-dependent AA. The incidence of CyAdependent AA in the general Japanese population was very low, despite the fact that the frequency of the DRBl*1501-DQA1*0102-DQB 1*0602 haplotype in the general Japanese population is as high as 5.6%.15 It is possible that the alleles in this haplotype in CyA-dependent AA may have a polymorphism that determines susceptibility to immune-mediated AA. Therefore, we examined PCR products derived from each HLA class I1 allele of selected patients in group A for the presence of sequence polymorphisms using the SSCP method (Fig 2) . Each gene fragment studied of all 5 patients (patients no. 1 to 5 ) showed the same mobility shift as that of a control subject homozygous with this haplotype.
DISCUSSION
Repeated response to CyA therapy in some patients with AA has been taken as evidence for an underlying immune mechanism in the pathogenesis of their AA. This study showed that a subset of AA patients that is characterized by a favorable but drug-dependent response to CyA is closely related to an HLA-class I1 haplotype of DRB1*1501-DQAl*0102-DQBl*0602. The strong correlation between CyA-dependent AA and this HLA class I1 haplotype supports the hypothesis that, in some patients with AA, immune mechanisms play a role in bone marrow failure.
We previously have shown that AA patients with HLA-DR2 are likely to respond to CyA therapy." However, the relationship between specific DRB 1 alleles corresponding to HLA-DR2 and response to CyA therapy has not been studied. In the Japanese, three DRBl alleles, including DRB1*1501, DRB1*1502, and DRB1*1602, determine the presentation of HLA-DR2. In the present analysis of CyAtreated AA patients, only those with DRBI*1501 showed a better response to CyA therapy than HLA-DR2-negative patients. Moreover, none of the 10 patients with DRB1*1501 obtained a sustained remission off CyA therapy, whereas 5 of 8 responders with DRB 1*1502 did. It is possible that the pathophysiology of AA may differ between DRB 1 * 1501-positive patients and DRl3 1 * 1502-positive patients, even though they share an HLA-DR serotype.
Although the association of a particular HLA-DR serotype with responsiveness to CyA therapy has been reported for Table 2 . Arrows indicate a band specific to each allele of DRB1*1501-DQA1+0102-DQB1+0602.
insulin-dependent diabetes mellitus by some investigators," this has not been confirmed by others.'X In the other autoimmune diseases, no association has been previously found between response to CyA therapy and HLA class 11. This may have occurred because most autoimmune diseases share a pathogenetic mechanism that is characterized by an association with an HLA class I1 haplotype, and responsiveness to CyA therapy is not influenced by a particular HLA class I1 allele. On the other hand, the pathogenesis of AA is clearly heterogeneous. Association of an HLA class I1 haplotype with a unique response to CyA therapy in patients with AA indicates that determining an HLA class I1 haplotype may be useful in identifying a subset of AA with a particular immunologic basis.
All patients with DRBI*1501 examined in this study shared a haplotype of DQA I *O 102-DQB 1 *0602 regardless of their response to CyA therapy. In addition, none of these alleles in patients with CyA-dependent AA showed polymorphisms specific to this type of AA when they were examined using the SSCP method. Therefore, it remains unknown which allele of the haplotype is associated with CyA-dependent AA. It is possible that other genes linked to this haplotype may be more important than these alleles. The fre-NAKAO ET AL quency for the DRB 1 * 1501 -DQA 1 "0102-DQB I *0602 haplotype is quoted at 3.3% (USA), 7.4% (Germany), 6.6% (France), 4.0% (Italy) as compared to 5.6% in the general Japanese population. l9.Is Studying similar patients with AA in a different ethnic group may be useful in determining an HLA class I1 allele or associated genes that may play an essential role in the development of CyA-dependent AA. 
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